This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Back
Filter 231 trials Clear all
Filter by:

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  • Status Recruiting
    Recruiting
  • Condition Relapsed or Refractory Multiple Myeloma
    Relapsed or Refractory Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Carfilzomib, Drug: Dexamethasone, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Birmingham, Alabama, United States

Brief Summary

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

  • Status Recruiting
    Recruiting
  • Condition Relapsed/Refractory Multiple Myeloma
    Relapsed/Refractory Multiple Myeloma
  • Phase Phase 1 Phase 2
    Phase 1 Phase 2
INTERVENTION

Biological: Adult differentiated autologous T-cells with anti-BCMA specificity

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: Adult differentiated autologous T-cells with anti-BCMA specificity

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Clinica Universidad de Navarra, Pamplona, Navarra, Spain

Brief Summary

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma, Amyloidosis
    Multiple Myeloma, Amyloidosis
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Lenalidomide, Drug: Pomalidomide

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Brief Summary

Patients with multiple myeloma (a type of blood cancer affecting the white blood cells) or amyloidosis (abnormal buildup of a protein called amyloid in the body) are often given treatment with the drugs lenalidomide or pomalidomide. Some patients may experience an allergic reaction to these drugs which would mean stopping the treatment. The purpose of this research study is to see how safe and useful desensitization is in allowing patients to receive further treatment with lenalidomide or pomalidomide.

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: ACY-241, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: ACY-241, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Arizona, Tucson, Arizona, United States

Brief Summary

This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma (MM).

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: POM, Drug: Steroids, Drug: PLD, Drug: CFZ, Drug: BTZ, Drug: CLA, Drug: CY

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

Brief Summary

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Winship Cancer Institute, Atlanta, Georgia, United States

Brief Summary

The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 2
    Phase 2
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Bortezomib, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Elotuzumab, Drug: Pomalidomide, Drug: Bortezomib, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Brief Summary

This research study is studying a combination of study drugs as a possible treatment for relapsed and refractory Multiple Myeloma. The interventions involved in this study are elotuzumab, pomalidomide, bortezomib, dexamethasone.

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Daratumumab Subcutaneous (SC) Administration, Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Daratumumab Subcutaneous (SC) Administration, Drug: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Pamplona, Spain

Brief Summary

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).

SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

  • Status Active, not recruiting
    Active, not recruiting
  • Condition Plasma Cell Myeloma
    Plasma Cell Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Drug: Isatuximab SAR650984, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Drug: Isatuximab SAR650984, Drug: Pomalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Investigational Site Number 840001, Scottsdale, Arizona, United States

Brief Summary

Primary Objectives: Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Part B: To evaluate the feasibility of isatuximab administered from a fixed infusion volume in combination with Pd as assessed by occurrence of grade ≥3 infusion associated reactions (IAR). Secondary Objectives: - To evaluate the infusion duration (Part B). - To evaluate the safety profile of the combination with isatuximab administration from fixed volume (Part B). - To evaluate immunogenicity of SAR650984 in combination with Pd (Part A and B). - To evaluate the pharmacokinetics (PK) of SAR650984 and its effect on the PK of pomalidomide when administered in combination (Part A). - To describe the efficacy of the combination of SAR650984 with Pd in terms of overall response rate and clinical benefit rate based on International Myeloma Working Group (IMWG) defined response criteria and the duration of response (Part A and B). - To assess the relationship between clinical effects (adverse event [AE] and/or tumor response) and CD38 receptor density at baseline (Part A).

BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

  • Status Recruiting
    Recruiting
  • Condition Multiple Myeloma
    Multiple Myeloma
  • Phase Phase 1
    Phase 1
INTERVENTION

Biological: PHE885

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
INTERVENTION

Biological: PHE885

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beth Israel Deaconess Medical Cente KS121, Boston, Massachusetts, United States

Brief Summary

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma